HMB-002, an antibody-based experimental treatment for von Willebrand disease (VWD) currently in early clinical testing, boosted levels of the protein whose deficiency causes VWD,…
News
Following rituximab treatment, people of African ancestry with immune thrombotic thrombocytopenic purpura (iTTP) experience a relapse significantly sooner than individuals with European ancestry, a…
High levels of anxiety and alexithymia, or difficulty in recognizing and expressing emotions, are associated with significantly poorer quality of life in people with primary…
The many types of von Willebrand disease may be much more common globally than previously thought, a large study of more than 800,000 people…
A combination of the medicines eltrombopag and cyclosporine A may be effective for controlling immune thrombocytopenia (ITP) that doesn’t respond well to initial treatment…
Scientists have developed a gene-editing therapy to selectively disable the genetic mutations responsible for Von Willebrand disease (VWD) type 2, regardless of subtype, potentially…
The shape of the ADAMTS13 enzyme during remission (a period when symptoms ease or disappear) may help predict which people with immune-mediated thrombotic thrombocytopenic…
Lipid, or fat, metabolism is altered in people with immune thrombocytopenia (ITP), resulting in distinct metabolic signatures that could help distinguish ITP patients from healthy…
A recent case report highlights the challenges of performing surgery in a patient with more than one bleeding disorder. Two doctors in Portugal described their…
More than half of individuals who recover from an acute episode of immune-mediated thrombotic thrombocytopenic purpura (iTTP) may have silent brain damage — where…
